SQZ BIOTECHNOLOGIES CO (SQZ) Stock Price & Overview
NYSE:SQZ • US78472W1045
Current stock price
The current stock price of SQZ is 0.435 USD. Today SQZ is up by 61.11%. In the past month the price decreased by -27.5%. In the past year, price decreased by -87.5%.
SQZ Key Statistics
- Market Cap
- 12.829M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.45
- Dividend Yield
- N/A
SQZ Stock Performance
SQZ Stock Chart
SQZ Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to SQZ. When comparing the yearly performance of all stocks, SQZ is a bad performer in the overall market: 96.18% of all stocks are doing better.
SQZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SQZ. SQZ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SQZ Earnings
SQZ Forecast & Estimates
6 analysts have analysed SQZ and the average price target is 19.38 USD. This implies a price increase of 4355.17% is expected in the next year compared to the current price of 0.435.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 65.7% for SQZ
SQZ Groups
Sector & Classification
SQZ Financial Highlights
Over the last trailing twelve months SQZ reported a non-GAAP Earnings per Share(EPS) of -2.45. The EPS increased by 7.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SQZ Ownership
SQZ Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.32 | 388.573B | ||
| AMGN | AMGEN INC | 15.57 | 194.674B | ||
| GILD | GILEAD SCIENCES INC | 16.1 | 179.261B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.53 | 117.486B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.93 | 80.247B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.48 | 42.494B | ||
| INSM | INSMED INC | N/A | 31.024B | ||
| NTRA | NATERA INC | N/A | 28.116B | ||
| BIIB | BIOGEN INC | 11.3 | 27.193B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.04 | 23.669B | ||
| MRNA | MODERNA INC | N/A | 21.299B | ||
| EXAS | EXACT SCIENCES CORP | 341.74 | 19.841B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SQZ
Company Profile
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-10-30. The firm is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
Company Info
IPO: 2020-10-30
SQZ BIOTECHNOLOGIES CO
200 Arsenal Yards Blvd, Suite 210
Watertown MASSACHUSETTS 02472 US
CEO: Armon Sharei
Employees: 53
Phone: 16177588672.0
SQZ BIOTECHNOLOGIES CO / SQZ FAQ
Can you describe the business of SQZ BIOTECHNOLOGIES CO?
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-10-30. The firm is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
Can you provide the latest stock price for SQZ BIOTECHNOLOGIES CO?
The current stock price of SQZ is 0.435 USD. The price increased by 61.11% in the last trading session.
Does SQZ stock pay dividends?
SQZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of SQZ stock?
SQZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting SQZ stock to perform?
6 analysts have analysed SQZ and the average price target is 19.38 USD. This implies a price increase of 4355.17% is expected in the next year compared to the current price of 0.435.
Can you provide the market cap for SQZ BIOTECHNOLOGIES CO?
SQZ BIOTECHNOLOGIES CO (SQZ) has a market capitalization of 12.83M USD. This makes SQZ a Nano Cap stock.
Can you provide the ownership details for SQZ stock?
You can find the ownership structure of SQZ BIOTECHNOLOGIES CO (SQZ) on the Ownership tab.